Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
APL-H5263 | Human | Human APRIL / TNFSF13 Protein, Fc Tag, active trimer |
|
|
|
APL-H82Q8 | Human | Biotinylated Human APRIL / TNFSF13 Protein, Avitag™,His Tag, active trimer (MALS verified) |
|
|
|
APL-C52D2 | Cynomolgus | Cynomolgus APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified) |
|
|
|
APL-H52D1 | Human | Human APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified) |
|
|
|
APL-H82F5 | Human | Biotinylated Human APRIL / TNFSF13 Protein, Fc,Avitag™ |
|
|
Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with an affinity constant of 1.88 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Telitacicept | RCT-18; RC-18; RCT18; RC18 | Approved | RemeGen Co Ltd | 泰爱 | Mainland China | Lupus Erythematosus, Systemic | RemeGen Co Ltd | 2021-03-09 | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Sjogren's Syndrome; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic | Details |
Telitacicept | RCT-18; RC-18; RCT18; RC18 | Approved | RemeGen Co Ltd | 泰爱 | Mainland China | Lupus Erythematosus, Systemic | RemeGen Co Ltd | 2021-03-09 | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Sjogren's Syndrome; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Atacicept | TACI-Ig | Phase 3 Clinical | Zymogenetics Inc | Glomerulonephritis, IGA; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Optic Neuritis; Lupus Erythematosus, Systemic | Details |
Zigakibart | BION-1301 | Phase 3 Clinical | Aduro Biotech Inc | Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma | Details |
Sibeprenlimab | VIS-649 | Phase 3 Clinical | Visterra Inc | Glomerulonephritis, IGA; Glomerulonephritis | Details |
Povetacicept | ALPN-303; ALPN 30x | Phase 2 Clinical | Alpine Immune Sciences Inc | Purpura, Thrombocytopenic, Idiopathic; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Lupus Nephritis; Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis | Details |
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
anti-TriPRIL CAR T-cell therapy(Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Multiple Myeloma | Details | |
AUR-200 | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
RO-7297089 | RO-7297089; AFM-26; RG-6296 | Phase 1 Clinical | Genentech Inc | Multiple Myeloma | Details |
APRIL CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
Atacicept | TACI-Ig | Phase 3 Clinical | Zymogenetics Inc | Glomerulonephritis, IGA; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Optic Neuritis; Lupus Erythematosus, Systemic | Details |
Zigakibart | BION-1301 | Phase 3 Clinical | Aduro Biotech Inc | Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma | Details |
Sibeprenlimab | VIS-649 | Phase 3 Clinical | Visterra Inc | Glomerulonephritis, IGA; Glomerulonephritis | Details |
Povetacicept | ALPN-303; ALPN 30x | Phase 2 Clinical | Alpine Immune Sciences Inc | Purpura, Thrombocytopenic, Idiopathic; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Lupus Nephritis; Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis | Details |
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
anti-TriPRIL CAR T-cell therapy(Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Multiple Myeloma | Details | |
AUR-200 | AUR-200; AUR200 | Phase 1 Clinical | Thunderbolt Pharma Inc | Autoimmune Diseases | Details |
RO-7297089 | RO-7297089; AFM-26; RG-6296 | Phase 1 Clinical | Genentech Inc | Multiple Myeloma | Details |
APRIL CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details |
This web search service is supported by Google Inc.